Envestnet Portfolio Solutions Inc. Trims Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Envestnet Portfolio Solutions Inc. lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 34.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,771 shares of the biopharmaceutical company's stock after selling 913 shares during the quarter. Envestnet Portfolio Solutions Inc.'s holdings in Regeneron Pharmaceuticals were worth $1,123,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in REGN. Pinney & Scofield Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth $25,000. OFI Invest Asset Management acquired a new position in Regeneron Pharmaceuticals during the 4th quarter worth about $28,000. Rakuten Securities Inc. grew its position in shares of Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 15 shares during the last quarter. Tompkins Financial Corp acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at about $32,000. Finally, Curat Global LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at about $32,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock traded down $1.98 during trading on Wednesday, hitting $520.29. The stock had a trading volume of 639,395 shares, compared to its average volume of 891,374. The stock's 50 day moving average is $556.44 and its two-hundred day moving average is $637.35. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,211.20. The stock has a market cap of $56.17 billion, a price-to-earnings ratio of 13.25, a price-to-earnings-growth ratio of 1.87 and a beta of 0.31. The company has a quick ratio of 4.03, a current ratio of 4.93 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The firm had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.40 billion. During the same period in the prior year, the company earned $9.55 EPS. The firm's quarterly revenue was down 3.7% on a year-over-year basis. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were paid a $0.88 dividend. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.68%. Regeneron Pharmaceuticals's dividend payout ratio is 8.96%.

Wall Street Analyst Weigh In

A number of research firms have weighed in on REGN. JPMorgan Chase & Co. decreased their target price on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating for the company in a research report on Monday, June 9th. Truist Financial cut their price target on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating on the stock in a research report on Wednesday, April 30th. Robert W. Baird lowered their price objective on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a research report on Friday, April 25th. UBS Group cut their target price on Regeneron Pharmaceuticals from $633.00 to $560.00 and set a "neutral" rating on the stock in a research report on Thursday, June 5th. Finally, Wall Street Zen downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 1st. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $836.48.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.